The role of EphA2 in ADAM17- and ionizing radiation-enhanced lung cancer cell migration.

Autor: Waller V; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Tschanz F; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Winkler R; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Pruschy M; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Mar 14; Vol. 13, pp. 1117326. Date of Electronic Publication: 2023 Mar 14 (Print Publication: 2023).

The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes Non-Small Cell Lung Cancer for Radiotherapy.

Autor: Tschanz F; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Bender S; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Telarovic I; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Waller V; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Speck RF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Pruschy M; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Publikováno v: Cancer research communications [Cancer Res Commun] 2021 Dec 22; Vol. 1 (3), pp. 164-177. Date of Electronic Publication: 2021 Dec 22 (Print Publication: 2021).

Tumor Oxygenation by Myo-Inositol Trispyrophosphate Enhances Radiation Response.

Autor: Grgic I; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University Zurich, Zurich, Switzerland., Tschanz F; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University Zurich, Zurich, Switzerland., Borgeaud N; Laboratory of the Swiss-Hepato-Pancreatico-Biliary (HPB) Centre, Department of Visceral Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Gupta A; Laboratory of the Swiss-Hepato-Pancreatico-Biliary (HPB) Centre, Department of Visceral Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Clavien PA; Laboratory of the Swiss-Hepato-Pancreatico-Biliary (HPB) Centre, Department of Visceral Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Guckenberger M; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University Zurich, Zurich, Switzerland., Graf R; Laboratory of the Swiss-Hepato-Pancreatico-Biliary (HPB) Centre, Department of Visceral Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Pruschy M; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University Zurich, Zurich, Switzerland. Electronic address: martin.pruschy@uzh.ch.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2021 Jul 15; Vol. 110 (4), pp. 1222-1233. Date of Electronic Publication: 2021 Feb 12.

Paracrine Placental Growth Factor Signaling in Response to Ionizing Radiation Is p53-Dependent and Contributes to Radioresistance.

Autor: Kazimova T; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Tschanz F; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Sharma A; Clinical Science Oncology, Medical & Scientific Affairs, Roche Diagnostics International Ltd., Rotkreuz Switzerland., Telarovic I; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Wachtel M; Department of Oncology and Children's Research Center, University Children's Hospital, Zurich, Switzerland., Pedot G; Department of Oncology and Children's Research Center, University Children's Hospital, Zurich, Switzerland., Schäfer B; Department of Oncology and Children's Research Center, University Children's Hospital, Zurich, Switzerland., Pruschy M; Laboratory for Applied Radiobiology, Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. martin.pruschy@uzh.ch.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2021 Jun; Vol. 19 (6), pp. 1051-1062. Date of Electronic Publication: 2021 Feb 22.

P1.06-15 Safety of Irradiation Combined with Intracavitary Cisplatin-Fibrin After Lung-Sparing Surgery in a Rat Model of Mesothelioma

Autor: Lauk, O., Kirschner, M., Meerang, M., Furrer, K., Grgic, I., Orlowski, V., Tschanz, F., Pruschy, M., Opitz, I.

Publikováno v: In Journal of Thoracic Oncology October 2019 14(10) Supplement:S484-S484